Relapse prevention for addictive behaviors

Substance Abuse: Treatment, Prevention, and Policy

Volumn 6, Issue 1, 2011, Pages

  Hendershot, Christian S ^a,b   Witkiewitz, Katie ^c   George, William H ^d   Marlatt, G Alan ^d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alcohol; Cognitive behavioral skills training; Continuing care; Drug use; Psychosocial intervention; Substance use treatment

Indexed keywords

ADDICTION; FORECASTING; HUMAN; METHODOLOGY; PSYCHOLOGICAL MODEL; RECURRENT DISEASE; REHABILITATION; REVIEW;

BEHAVIOR, ADDICTIVE; FORECASTING; HUMANS; MODELS, PSYCHOLOGICAL; RECURRENCE; TERTIARY PREVENTION;

EID: 79960563488     PISSN: None     EISSN: 1747597X     Source Type: Journal    
DOI: 10.1186/1747-597X-6-17     Document Type: Review

References (141)

1. Brandon TH, Vidrine JI, Litvin EB. Relapse and relapse prevention. Annu Rev Clin Psychol 2007, 3:257-284. 10.1146/annurev.clinpsy.3.022806.091455, 17716056.
2. Orleans CT. Promoting the maintenance of health behavior change: Recommendations for the next generation of research and practice. Health Psychol 2000, 19:76-83.
3. Polivy J, Herman CP. If at first you don't succeed: False hopes of self-change. Am Psychol 2002, 57:677-689.
4. Miller WR, Westerberg VS, Harris RJ, Tonigan JS. What predicts relapse? Prospective testing of antecedent models. Addiction 1996, 91(Suppl):S155-172.
5. Hunt WA, Barnett LW, Branch LG. Relapse rates in addiction programs. J Clin Psychol 1971, 27:455-456. 10.1002/1097-4679(197110)27:4<455::AID-JCLP2270270412>3.0.CO;2-R, 5115648.
6. Kirshenbaum AP, Olsen DM, Bickel WK. A quantitative review of the ubiquitous relapse curve. J Subst Abuse Treat 2009, 36:8-17. 10.1016/j.jsat.2008.04.001, 3151675, 18571890.
7. Marlatt GA, Gordon JR. Determinants of relapse: Implications for the maintenance of behavior change. Behavioral Medicine: Changing health lifestyles 1980, 410-452. New York: Brunner/Mazel, Davidson PO, Davidson SM.
8. Witkiewitz K, Marlatt GA. Relapse prevention for alcohol and drug problems: That was Zen, this is Tao. Am Psychol 2004, 59:224-235.
9. Hendershot CS, Marlatt GA, George WH. Relapse prevention and the maintenance of optimal health. The Handbook of Health Behavior Change 2007. New York: Springer Publishing Co, Shumaker S, Ockene JK, Riekert K, 3.
10. Witkiewitz K, Marlatt GA. Therapist's Guide to Evidence-Based Relapse Prevention 2007, London: Academic Press.
11. Marlatt GA, Witkiewitz K. Relapse Prevention for Alcohol and Drug Problems 2005, 1-44. Relapse prevention: Maintenance strategies in the treatment of addictive behaviors, Marlatt G Alan, Donovan Dennis M, 2, 2005..
12. Brownell KD, Marlatt GA, Lichtenstein E, Wilson GT. Understanding and preventing relapse. Am Psychol 1986, 41:765-782.
13. Miller WR. Section I. theoretical perspectives on relapse: What is a relapse? Fifty ways to leave the wagon. Addiction 1996, 91:S15-S27. 10.1111/j.1360-0443.1996.tb02324.x, 8997778.
14. Maisto SA, Connors GJ. Relapse in the addictive behaviors: Integration and future directions. Clin Psychol Rev 2006, 26:229-231. 10.1016/j.cpr.2005.11.009, 16360255.
15. Piasecki TM. Relapse to smoking. Clin Psychol Rev 2006, 26:196-215. 10.1016/j.cpr.2005.11.007, 16352382.
16. Marlatt GA, Gordon JR. Relapse prevention: Maintenance strategies in the treatment of addictive behaviors 1985, New York: Guilford Press.
17. McGovern MP, Wrisley BR, Drake RE. Relapse of substance use disorder and its prevention among persons with co-occurring disorders. Psychiatr Serv 2005, 56:1270-1273. 10.1176/appi.ps.56.10.1270, 16215194.
18. Project MATCH Research Group Matching alcoholism treatments to client heterogeneity: Project MATCH Posttreatment drinking outcomes. J Stud Alcohol 1997, 58:7-29. Project MATCH Research Group.
19. COMBINE Study Research Group Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res 2003, 27:1107-1122. COMBINE Study Research Group.
20. Rawson RA, Shoptaw SJ, Obert JL, McCann MJ, Hasson AL, Marinelli-Casey PJ, Brethen PR, Ling W. An intensive outpatient approach for cocaine abuse treatment. The Matrix model. J Subst Abuse Treat 1995, 12:117-127. 10.1016/0740-5472(94)00080-B, 7623389.
21. Miller WR, Wilbourne PL. Mesa Grande: A methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 2002, 97:265-277. 10.1046/j.1360-0443.2002.00019.x, 11964100.
22. Cummings C, Gordon JR, Marlatt GA. Relapse: Strategies of prevention and prediction. The addictive behaviors: Treatment of alcoholism, drug abuse, smoking, and obesity 1980, 291-321. Oxford: Pergamon.
23. Dimeff LA, Marlatt GA. Preventing relapse and maintaining change in addictive behaviors. Clin Psychol Sci Prac 1998, 5:513-525.
24. Larimer ME, Palmer RS, Marlatt GA. Relapse prevention: An overview of Marlatt's cognitive-behavioral model. Alcohol Res Health 1999, 23:151-160.
25. Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC. Addiction Motivation Reformulated: An Affective Processing Model of Negative Reinforcement. Psychol Rev 2004, 111:33-51.
26. Bandura A. Self-efficacy: The exercise of control 1997, New York: Freeman.
27. Goldman MS, Darkes J, Del Boca FK. Expectancy mediation of biopsychosocial risk for alcohol use and alcoholism 1999, 233-262. Washington, DC, US: American Psychological Association.; 1999, Kirsch, Irving, How expectancies shape experience.
28. Rothman AJ. Toward a theory-based analysis of behavioral maintenance. Health Psychol 2000, 19:64-69.
29. Marlatt GA, Donovan DM. Relapse prevention: Maintenance strategies in the treatment of addictive behaviors 2005, New York: Guilford, 2.
30. Donovan DM, Marlatt GA. Assessment of addictive behaviors 2005, New York: Guilford, 2.
31. Hufford MR, Witkiewitz K, Shields AL, Kodya S, Caruso JC. Relapse as a nonlinear dynamic system: Application to patients with alcohol use disorders. J Abnorm Psychol 2003, 112:219-227.
32. Bouton ME. A learning theory perspective on lapse, relapse, and the maintenance of behavior change. Health Psychol 2000, 19:57-63.
33. Witkiewitz K, Marlatt GA. Modeling the complexity of post-treatment drinking: it's a rocky road to relapse. Clin Psychol Rev 2007, 27:724-738. 10.1016/j.cpr.2007.01.002, 1995671, 17355897.
34. Witkiewitz K, van der Maas HLJ, Hufford MR, Marlatt GA. Nonnormality and divergence in posttreatment alcohol use: Reexamining the Project MATCH data "another way.". J Abnorm Psychol 2007, 116:378-394. 2048690, 17516769.
35. Carroll KM. Relapse prevention as a psychosocial treatment: A review of controlled clinical trials. Exp Clin Psychopharmacol 1996, 4:46-54.
36. Irvin JE, Bowers CA, Dunn ME, Wang MC. Efficacy of relapse prevention: A meta-analytic review. J Consult Clin Psychol 1999, 67:563-570.
37. McCrady BS. Alcohol use disorders and the Division 12 Task Force of the American Psychological Association. Psychol Addict Behav 2000, 14:267-276.
38. Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2009, CD003999.
39. Lancaster T, Hajek P, Stead LF, West R, Jarvis MJ. Prevention of relapse after quitting smoking: a systematic review of trials. Arch Intern Med 2006, 166:828-835. 10.1001/archinte.166.8.828, 16636207.
40. Agboola S, McNeill A, Coleman T, Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010, 105:1362-1380. 10.1111/j.1360-0443.2010.02996.x, 20653619.
41. Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs 2009, 70:516-527. 2696292, 19515291.
42. Niaura R. Cognitive social learning and related perspectives on drug craving. Addiction 2000, 95(Suppl 2):S155-163.
43. Shiffman S, Balabanis MH, Paty JA, Engberg J, Gwaltney CJ, Liu KS, Gnys M, Hickcox M, Paton SM. Dynamic effects of self-efficacy on smoking lapse and relapse. Health Psychol 2000, 19:315-323.
44. Stone AA, Shiffman S. Ecological momentary assessment (EMA) in behavorial medicine. Ann Behav Med 1994, 16:199-202.
45. Gwaltney CJ, Shiffman S, Balabanis MH, Paty JA. Dynamic Self-Efficacy and Outcome Expectancies: Prediction of Smoking Lapse and Relapse. J Abnorm Psychol 2005, 114:661-675.
46. Gwaltney CJ, Shiffman S, Sayette MA. Situational Correlates of Abstinence Self-Efficacy. J Abnorm Psychol 2005, 114:649-660.
47. Gwaltney CJ, Metrik J, Kahler CW, Shiffman S. Self-efficacy and smoking cessation: a meta-analysis. Psychol Addict Behav 2009, 23:56-66.
48. Herd N, Borland R. The natural history of quitting smoking: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction 2009, 104:2075-2087. 10.1111/j.1360-0443.2009.02731.x, 19922573.
49. Herd N, Borland R, Hyland A. Predictors of smoking relapse by duration of abstinence: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction 2009, 104:2088-2099. 10.1111/j.1360-0443.2009.02732.x, 19922574.
50. Katz EC, Fromme K, D'Amico EJ. Effects of outcome expectancies and personality on young adults' illicit drug use, heavy drinking, and risky sexual behavior. Cognit Ther Res 2000, 24:1-22.
51. Hendershot CS, Neighbors C, George WH, McCarthy DM, Wall TL, Liang T, Larimer ME. ALDH2, ADH1B and alcohol expectancies: integrating genetic and learning perspectives. Psychol Addict Behav 2009, 23:452-463. 2761721, 19769429.
52. McCarthy DM, Wall TL, Brown SA, Carr LG. Integrating biological and behavioral factors in alcohol use risk: The role of ALDH2 status and alcohol expectancies in a sample of Asian Americans. Exp Clin Psychopharmacol 2000, 8:168-175.
53. Cohen LM, McCarthy DM, Brown SA, Myers MG. Negative affect combines with smoking outcome expectancies to predict smoking behavior over time. Psychol Addict Behav 2002, 16:91-97.
54. Stacy AW, Wiers RW. Implicit cognition and addiction: a tool for explaining paradoxical behavior. Annu Rev Clin Psychol 2010, 6:551-575. 10.1146/annurev.clinpsy.121208.131444, 20192786.
55. Wiers RW, Stacy AW. Handbook of implicit cognition and addiction 2006, Handbook of implicit cognition and addiction. Thousand Oaks, CA: Sage Publications, 2006..
56. Field M, Wiers RW, Christiansen P, Fillmore MT, Verster JC. Acute alcohol effects on inhibitory control and implicit cognition: implications for loss of control over drinking. Alcohol Clin Exp Res 2010, 34:1346-1352. 2999764, 20491732.
57. Wiers RW, Bartholow BD, van den Wildenberg E, Thush C, Engels RC, Sher KJ, Grenard J, Ames SL, Stacy AW. Automatic and controlled processes and the development of addictive behaviors in adolescents: A review and a model. Pharmacol Biochem Behav 2007, 86:263-283. 10.1016/j.pbb.2006.09.021, 17116324.
58. Kramer DA, Goldman MS. Using a modified Stroop task to implicitly discern the cognitive organization of alcohol expectancies. J Abnorm Psychol 2003, 112:171-175.
59. McCarthy DM, Thompsen DM. Implicit and Explicit Measures of Alcohol and Smoking Cognitions. Psychol Addict Behav 2006, 20:436-444.
60. Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH. Attentional bias predicts outcome in smoking cessation. Health Psychol 2003, 22:378-387. 2244587, 12940394.
61. Marissen MA, Franken IH, Waters AJ, Blanken P, van den Brink W, Hendriks VM. Attentional bias predicts heroin relapse following treatment. Addiction 2006, 101:1306-1312. 10.1111/j.1360-0443.2006.01498.x, 16911730.
62. Schoenmakers TM, de Bruin M, Lux IF, Goertz AG, Van Kerkhof DH, Wiers RW. Clinical effectiveness of attentional bias modification training in abstinent alcoholic patients. Drug Alcohol Depend 2010, 109:30-36. 10.1016/j.drugalcdep.2009.11.022, 20064698.
63. Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Smoking Withdrawal Dynamics: III. Correlates of Withdrawal Heterogeneity. Exp Clin Psychopharmacol 2003, 11:276-285.
64. Piasecki TM, Niaura R, Shadel WG, Abrams D, Goldstein M, Fiore MC, Baker TB. Smoking withdrawal dynamics in unaided quitters. J Abnorm Psychol 2000, 109:74-86.
65. Piasecki TM, Fiore MC, Baker TB. Profiles in discouragement: Two studies of variability in the time course of smoking withdrawal symptoms. J Abnorm Psychol 1998, 107:238-251. 2000.
66. Baker TB, Japuntich SJ, Hogle JM, McCarthy DE, Curtin JJ. Pharmacologic and Behavioral Withdrawal from Addictive Drugs. Curr Dir Psychol Sci 2006, 15:232-236.
67. Marlatt GA. Craving for alcohol, loss of control, and relapse: A cognitive-behavioral analysis. Alcoholism: New directions in behavioral research and treatment 1978, 271-314. New York: Plenum, Nathan PE, Marlatt GA, Loberg T.
68. Shiffman S, Hickcox M, Paty JA, Gnys M, Kassel JD, Richards TJ. Progression from a smoking lapse to relapse: Prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. J Consult Clin Psychol 1996, 64:993-1002.
69. Brown RA, Lejuez CW, Kahler CW, Strong DR. Distress tolerance and duration of past smoking cessation attempts. J Abnorm Psychol 2002, 111:180-185.
70. Shiffman S, Waters AJ. Negative Affect and Smoking Lapses: A Prospective Analysis. J Consult Clin Psychol 2004, 72:192-201.
71. Gwaltney CJ, Shiffman S, Normal GJ, Paty JA, Kassel JD, Gnys M, Hickcox M, Waters A, Balabanis M. Does smoking abstinence self-efficacy vary across situations? Identifying context-specificity within the Relapse Situation Efficacy Questionnaire. J Consult Clin Psychol 2001, 69:516-527.
72. Witkiewitz K, Villarroel NA. Dynamic association between negative affect and alcohol lapses following alcohol treatment. J Consult Clin Psychol 2009, 77:633-644. 2911993, 19634957.
73. Armeli S, Tennen H, Affleck G, Kranzler HR. Does affect mediate the association between daily events and alcohol use?. J Stud Alcohol 2000, 61:862-871.
74. Hussong AM, Hicks RE, Levy SA, Curran PJ. Specifying the relations between affect and heavy alcohol use among young adults. J Abnorm Psychol 2001, 110:449-461.
75. Morgenstern J, Longabaugh R. Cognitive-behavioral treatment for alcohol dependence: A review of evidence for its hypothesized mechanisms of action. Addiction 2000, 95:1475-1490. 10.1046/j.1360-0443.2000.951014753.x, 11070524.
76. O'Connell KA, Hosein VL, Schwartz JE, Leibowitz RQ. How Does Coping Help People Resist Lapses During Smoking Cessation?. Health Psychol 2007, 26:77-84.
77. Litt MD, Kadden RM, Stephens RS. Coping and Self-Efficacy in Marijuana Treatment: Results From the Marijuana Treatment Project. J Consult Clin Psychol 2005, 73:1015-1025.
78. Muraven M, Baumeister RF. Self-regulation and depletion of limited resources: Does self-control resemble a muscle?. Psychol Bull 2000, 126:247-259.
79. Muraven M, Collins RL, Shiffman S, Paty JA. Daily Fluctuations in Self-Control Demands and Alcohol Intake. Psychol Addict Behav 2005, 19:140-147.
80. Muraven M, Collins RL, Morsheimer ET, Shiffman S, Paty JA. The Morning After: Limit Violations and the Self-Regulation of Alcohol Consumption. Psychol Addict Behav 2005, 19:253-262.
81. Muraven M. Practicing self-control lowers the risk of smoking lapse. Psychol Addict Behav 2010, 24:446-452.
82. Witkiewitz K, Hartzler B, Donovan D. Matching motivation enhancement treatment to client motivation: re-examining the Project MATCH motivation matching hypothesis. Addiction 2010, 105:1403-1413. 10.1111/j.1360-0443.2010.02954.x, 3157315, 20491723.
83. Ho MK, Goldman D, Heinz A, Kaprio J, Kreek MJ, Li MD, Munafo MR, Tyndale RF. Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clin Pharmacol Ther 2010, 88:779-791. 10.1038/clpt.2010.175, 20981002.
84. Sturgess JE, George TP, Kennedy JL, Heinz A, Muller DJ. Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addict Biol 2011,
85. Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J, DeMichele A, Bunin G, Strom BL, Rebbeck TR. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics 2005, 15:393-398. 10.1097/01213011-200506000-00004, 1262648, 15900212.
86. Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafo MR. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 2007, 16:1065-1069. 10.1158/1055-9965.EPI-06-0936, 2031911, 17548664.
87. Munafo MR, Johnstone EC, Guo B, Murphy MF, Aveyard P. Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenet Genomics 2008, 18:121-128. 10.1097/FPC.0b013e3282f44daa, 18192898.
88. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, Bergen AW, Swan GE, Tyndale RF, Benowitz NL, Lerman C. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 2008, 17:2834-2848. 10.1093/hmg/ddn181, 2525499, 18593715.
89. Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL. Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch. Cancer Epidemiol Biomarkers Prev 2009, 18:2608-2612. 10.1158/1055-9965.EPI-09-0166, 2759850, 19755656.
90. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH, Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein LH. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003, 22:541-548.
91. Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields PG, Kaufmann V, Redden D, Benowitz N, Berrettini WH. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004, 4:184-192. 10.1038/sj.tpj.6500238, 15007373.
92. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP. A Functional Polymorphism of the mu-Opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28:1546-1552. 10.1038/sj.npp.1300219, 12813472.
93. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008, 65:135-144. 10.1001/archpsyc.65.2.135, 2666924, 18250251.
94. Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, Pinto A, Berrettini W, Lerman C. Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine Tob Res 2007, 9:1237-1241. 10.1080/14622200701648367, 17978999.
95. Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 2004, 28:1789-1795. 10.1097/01.ALC.0000148114.34000.B9, 15608594.
96. Filbey FM, Ray L, Smolen A, Claus ED, Audette A, Hutchison KE. Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res 2008, 32:1113-1123. 10.1111/j.1530-0277.2008.00692.x, 2856650, 18540916.
97. van den Wildenberg E, Wiers RW, Dessers J, Janssen RGJH, Lambrichs EH, Smeets HJM, van Breukelen GJP. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 2007, 31:1-10. 10.1111/j.1530-0277.2006.00258.x, 17207095.
98. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 2010,
99. Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, Daoust M, van den Brink W. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol 2009, 14:328-337. 10.1111/j.1369-1600.2009.00159.x, 19523047.
100. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 2006, 31:1310-1317.
101. Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L, Paris L. Olanzapine reduces craving for alcohol: A DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 2003, 28:1882-1888. 10.1038/sj.npp.1300264, 12888781.
102. Bauer LO, Covault J, Harel O, Das S, Gelernter J, Anton R, Kranzler HR. Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res 2007, 31:1780-1787. 10.1111/j.1530-0277.2007.00517.x, 17949392.
103. Wojnar M, Brower KJ, Strobbe S, Ilgen M, Matsumoto H, Nowosad I, Sliwerska E, Burmeister M. Association between Val66Met brain-derived neurotrophic factor (BDNF) gene polymorphism and post-treatment relapse in alcohol dependence. Alcohol Clin Exp Res 2009, 33:693-702. 10.1111/j.1530-0277.2008.00886.x, 2928673, 19170664.
104. Hendershot CS, Lindgren KP, Liang T, Hutchison KE. COMT and ALDH2 polymorphisms moderate associations of implicit drinking motives with alcohol use. Addict Biol 2011,
105. Hendershot CS, Witkiewitz K, George WH, Wall TL, Otto JM, Liang T, Larimer ME. Evaluating a cognitive model of ALDH2 and drinking behavior. Alcohol Clin Exp Res 2011, 35:91-98. 10.1111/j.1530-0277.2010.01325.x, 21039630.
106. Miranda R, Ray L, Justus A, Meyerson LA, Knopik VS, McGeary J, Monti PM. Initial evidence of an association between OPRM1 and adolescent alcohol misuse. Alcohol Clin Exp Res 2010, 34:112-122. 10.1111/j.1530-0277.2009.01073.x, 19860800.
107. Wiers RW, Rinck M, Dictus M, van den Wildenberg E. Relatively strong automatic appetitive action-tendencies in male carriers of the OPRM1 G-allele. Genes Brain Behav 2009, 8:101-106. 10.1111/j.1601-183X.2008.00454.x, 19016889.
108. Young RM, Lawford BR, Feeney GFX, Ritchie T, Noble EP. Alcohol-related expectancies are associated with the D2 dopamine receptor and GABA receptor beta3 subunit genes. Psychiatry Res 2004, 127:171-183. 10.1016/j.psychres.2003.11.004, 15296817.
109. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, David SP, Niaura R, Lerman C. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 2008, 65:683-693. 10.1001/archpsyc.65.6.683, 2430596, 18519826.
110. Hendershot CS, Otto JM, Collins SE, Liang T, Wall TL. Evaluation of a brief web-based genetic feedback intervention for reducing alcohol-related health risks associated with ALDH2. Ann Behav Med 2010, 40:77-88. 10.1007/s12160-010-9207-3, 2977977, 20652463.
111. Marteau TM, Munafo MR, Aveyard P, Hill C, Whitwell S, Willis TA, Crockett RA, Hollands GJ, Johnstone EC, Wright AJ, et al. Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence. BMC Public Health 2010, 10:680. 10.1186/1471-2458-10-680, 2996370, 21062464.
112. Witkiewitz K, Marlatt GA, Walker D. Mindfulness-Based Relapse Prevention for Alcohol and Substance Use Disorders. J Cogn Psychother 2005, 19:211-228.
113. Zgierska A, Rabago D, Chawla N, Kushner K, Koehler R, Marlatt A. Mindfulness meditation for substance use disorders: a systematic review. Subst Abus 2009, 30:266-294. 10.1080/08897070903250019, 2800788, 19904664.
114. Lau MA, Segal ZV. Mindfulness-based cognitive therapy as a relapse prevention approach to depression. Therapist's Guide to Evidence-Based Relapse Prevention 2007, London: Academic Press, Witkiewitz K, Marlatt GA.
115. Marlatt GA. Buddhist philosophy and the treatment of addictive behavior. Cogn Behav Pract 2002, 9:44-49.
116. Bowen S, Witkiewitz K, Dillworth TM, Chawla N, Simpson TL, Ostafin BD, Larimer ME, Blume AW, Parks GA, Marlatt GA. Mindfulness meditation and substance use in an incarcerated population. Psychol Addict Behav 2006, 20:343-347.
117. Bowen S, Chawla N, Collins SE, Witkiewitz K, Hsu S, Grow J, Clifasefi S, Garner M, Douglass A, Larimer ME, Marlatt A. Mindfulness-based relapse prevention for substance use disorders: a pilot efficacy trial. Subst Abus 2009, 30:295-305. 10.1080/08897070903250084, 19904665.
118. Witkiewitz K, Bowen S. Depression, craving, and substance use following a randomized trial of mindfulness-based relapse prevention. J Consult Clin Psychol 2010, 78:362-374.
119. Maisto SA, Connors GJ, Zywiak WH. Replication and extension of Marlatt's taxonomy: Construct validation analyses on the Marlatt typology of relapse precipitants. Addiction 1996, 91:S89-S97. 10.1111/j.1360-0443.1996.tb02329.x, 8997783.
120. Stout RL, Longabaugh R, Rubin A. Replication and extension of Marlatt's taxonomy: Predictive validity of Marlatt's relapse taxonomy versus a more general relapse code. Addiction 1996, 91:S99-S110. 10.1111/j.1360-0443.1996.tb02330.x, 8997784.
121. Donovan DM. Commentary on replications of Marlatt's taxonomy: Marlatt's classification of relapse precipitants: Is the emperor still wearing clothes?. Addiction 1996, 91:S131-S137. 10.1111/j.1360-0443.1996.tb02333.x, 8997787.
122. Hunter-Reel D, McCrady B, Hildebrandt T. Emphasizing interpersonal factors: an extension of the Witkiewitz and Marlatt relapse model. Addiction 2009, 104:1281-1290. 10.1111/j.1360-0443.2009.02611.x, 2714871, 19549057.
123. Stanton M. Relapse Prevention Needs More Emphasis on Interpersonal Factors. Am Psychol 2005, 60:340-341.
124. McKay JR, Franklin TR, Patapis N, Lynch KG. Conceptual, methodological, and analytical issues in the study of relapse. Clin Psychol Rev 2006, 26:109-127. 10.1016/j.cpr.2005.11.002, 16371242.
125. Walls TA, Schafer JL. Models for Intensive Longitudinal Data 2006, New York: Oxford University Press.
126. Longabaugh R, Donovan DM, Karno MP, McCrady BS, Morgenstern J, Tonigan JS. Active ingredients: How and why evidence-based alcohol behavioral treatment interventions work. Alcohol Clin Exp Res 2005, 29:235-247. 10.1097/01.ALC.0000153541.78005.1F, 15714046.
127. Witkiewitz K, Villarroel NA, Hartzler B, Donovan DM. Drinking outcomes following drink refusal skills training: Differential effects for African American and non-Hispanic White clients. Psychol Addict Behav 2011, 25:162-167.
128. Witkiewitz K, Bowen S, Donovan DM. Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence. J Consult Clin Psychol 2011, 79:54-63.
129. Kazdin AE, Nock MK. Delineating mechanisms of change in child and adolescent therapy: methodological issues and research recommendations. J Child Psychol Psychiatry 2003, 44:1116-1129. 10.1111/1469-7610.00195, 14626454.
130. Morgenstern J, Longabaugh R. Cognitive-behavioral treatment for alcohol dependence: A review of evidence for its hypothesized mechanisms of action. Addiction 2000, 95:1475-1490. 10.1046/j.1360-0443.2000.951014753.x, 11070524.
131. Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 2004, 47(Suppl 1):3-13.
132. Paulus MP, Tapert SF, Schuckit MA. Neural Activation Patterns of Methamphetamine-Dependent Subjects During Decision Making Predict Relapse. Arch Gen Psychiatry 2005, 62:761-768. 10.1001/archpsyc.62.7.761, 15997017.
133. Mann K, Kiefer F, Smolka M, Gann H, Wellek S, Heinz A. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. Alcohol Clin Exp Res 2009, 33:674-683. 10.1111/j.1530-0277.2008.00884.x, 19170666.
134. Durazzo TC, Gazdzinski S, Mon A, Meyerhoff DJ. Cortical perfusion in alcohol-dependent individuals during short-term abstinence: Relationships to resumption of hazardous drinking after treatment. Alcohol 2010, 44:201-210. 10.1016/j.alcohol.2010.03.003, 3038637, 20682188.
135. Brandon TH, Collins BN, Juliano LM, Lazev AB. Preventing relapse among former smokers: A comparison of minimal interventions through telephone and mail. J Consult Clin Psychol 2000, 68:103-113.
136. Brandon TH, Meade CD, Herzog TA, Chirikos TN, Webb MS, Cantor AB. Efficacy and cost-effectiveness of a minimal intervention to prevent smoking relapse: Dismantling the effects of amount of content versus contact. J Consult Clin Psychol 2004, 72:797-808.
137. Shadel WG, Cervone D. Evaluating social-cognitive mechanisms that regulate self-efficacy in response to provocative smoking cues: An experimental investigation. Psychol Addict Behav 2006, 20:91-96.
138. McLellan AT. Have we evaluated addiction treatment correctly? Implications from a chronic care perspective. Addiction 2002, 97:249-252. 10.1046/j.1360-0443.2002.00127.x, 11964098.
139. Humphreys K, McLellan AT. A policy-oriented review of strategies for improving the outcomes of services for substance use disorder patients*. Addiction 2011,
140. McKay JR, Carise D, Dennis ML, Dupont R, Humphreys K, Kemp J, Reynolds D, White W, Armstrong R, Chalk M, et al. Extending the benefits of addiction treatment: practical strategies for continuing care and recovery. J Subst Abuse Treat 2009, 36:127-130. 10.1016/j.jsat.2008.10.005, 2744393, 19161893.
141. Office of National Drug Control Policy National Drug Control Strategy for 2010. Office of National Drug Control Policy., http://www.ondcp.gov